Drug Testing in Pain Management and Substance Use Disorder Treatment — CPB 0965 | AETNA Coverage Update

TL;DR: Aetna, a CVS Health company, modified CPB 0965 governing drug testing in pain management and substance use disorder treatment, effective March 4, 2026. Billing teams need to audit which CPT and HCPCS codes they're submitting — because the covered list is short and the excluded list is long.

This update to the Aetna drug testing coverage policy affects anyone billing presumptive or definitive urine drug tests under CPT codes 80305, 80306, 80307, 80375, 80376, and 80377, as well as definitive testing under HCPCS G0480–G0483 and G0659. The policy is narrow by design. Aetna draws a hard line between clinically justified, individualized testing and the kind of standing-order, panel-heavy billing patterns that have driven audit activity in this space for years. If your pain management or SUD program runs broad drug panels as a matter of routine, this coverage policy will generate claim denials.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Drug Testing in Pain Management and Substance Use Disorder Treatment
Policy Code	CPB 0965
Change Type	Modified
Effective Date	March 4, 2026
Impact Level	High
Specialties Affected	Pain Management, Addiction Medicine, Primary Care (SUD programs), Behavioral Health
Key Action	Audit all drug testing orders for individualization — eliminate any standing or blanket orders before billing under 80305–80307 or G0480–G0483

---

Aetna Drug Testing Coverage Criteria and Medical Necessity Requirements 2026

CPB 0965 Aetna sets two tiers of covered testing: presumptive and definitive. Medical necessity applies differently to each, and the sequencing matters for reimbursement.

Presumptive testing (CPT 80305, 80306, 80307) is covered for members enrolled in a chronic pain program or substance use disorder program when at least one of these conditions exists:

The program-enrollment requirement is not incidental. This coverage policy does not extend to drug monitoring for patients on opioids or controlled substances outside a formal pain management or SUD program. Monitoring a patient on benzodiazepines for anxiety or amphetamines for ADHD falls outside this CPB entirely.

Individualization is the critical word here. Aetna requires that testing target only the substances relevant to the member's specific treatment plan. Clinical documentation must spell out how the results will guide clinical decisions. Frequency is also individualized — there's no set schedule, and blanket standing orders won't pass medical necessity review.

Definitive testing (CPT 80375, 80376, 80377; HCPCS G0480, G0481, G0482, G0483, G0659) requires that the member first meet medical necessity criteria for presumptive testing. Then, at least one of these additional triggers applies:

Read that list carefully. Definitive testing is a second step, not a default. Ordering definitive and presumptive tests simultaneously for the same drug — without letting presumptive results drive the decision — fails medical necessity under this policy. That pattern is exactly what Aetna is targeting.

---

Aetna Drug Testing Exclusions and Non-Covered Indications

This is where the billing risk lives. The not-covered list in CPB 0965 is extensive, and it maps directly to billing patterns that are common in high-volume labs and pain clinics.

Aetna explicitly excludes the following from coverage under this policy:

The pharmacogenomic exclusions deserve a separate sentence. Aetna is not covering CYP450 gene analysis (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5) or MTHFR testing under this CPB. If your lab or clinic has been billing these alongside drug testing for pain patients, expect claim denials without an alternative coverage basis.

CPT 0007U — which combines presumptive testing with automatic definitive confirmation of positives — is also excluded. That bundled approach directly conflicts with Aetna's requirement that definitive testing be ordered only after reviewing presumptive results.

---

Coverage Indications at a Glance

---

Aetna Drug Testing Billing Guidelines and Action Items 2026

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for Drug Testing Under CPB 0965

Covered CPT Codes (When Selection Criteria Are Met)

Covered HCPCS Codes (When Selection Criteria Are Met)

Not Covered CPT Codes Under CPB 0965

Key ICD-10-CM Diagnosis Codes

---